GlassScriptPhysician profile
Sevwandi G De Silva
NPI 1003343799
$2,227.21
in general payments reported to CMS, 2019-2025
9 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.73 · 2021: $76.99 · 2022: $909 · 2024: $112 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $457.04 | 2022-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Intuitive Surgical, INC. | $402.25 | 2022-2025 | |
| Pinnacle Biologics, INC | $306.64 | 2024-2025 | Photofrin |
| Genzyme Corporation | $285.43 | 2022-2025 | |
| Astellas Pharma US INC | $248.98 | 2021-2022 | |
| Penumbra, INC. | $162.74 | 2025 | Indigo System |
| Galvanize Therapeutics, INC | $135.52 | 2025 | Aliya System |
| Erbe USA INC | $108.48 | 2025 | Cryo2 |
| Ethicon INC. | $99.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sevwandi De Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.